Erratum to “Antiviral prophylaxis and treatment (excluding HIV therapy)”

Erratum to “Antiviral prophylaxis and treatment (excluding HIV therapy)”

Journal of Clinical Virology 26 (2003) 117 /120 www.elsevier.com/locate/jcv Erratum Erratum to ‘‘Antiviral prophylaxis and treatment (excluding HIV...

63KB Sizes 1 Downloads 73 Views

Journal of Clinical Virology 26 (2003) 117 /120 www.elsevier.com/locate/jcv

Erratum

Erratum to ‘‘Antiviral prophylaxis and treatment (excluding HIV therapy)’’ [Journal of Clinical Virology 25 (2002) 241 266] /

S.M.L. Waugh a,*, D. Pillay b, D. Carrington c, W.F. Carman a a

West of Scotland Specialist Virology Centre, Gartnavel General Hospital, Great Western Road, Glasgow G12 OYN, UK b Public Health Laboratory, Birmingham Heartlands Hospital, Bordesley Green East, Birmingham B9 5SS, UK c Public Health Laboratory, Myrtle Road, Kingsdown, Bristol BS2 8EL, UK Accepted 5 August 2002

The publisher regrets that Table 2 in this article was printed incorrectly. The correct Table 2 is shown on the following 3 pages. The fully corrected article is also available free online at http://www.clinical-virology.org



PII of original article: S 1 3 8 6 - 6 5 3 2 ( 0 2 ) 0 0 1 5 1 - 8 * Corresponding author.

1386-6532/03/$ - see front matter # 2003 Elsevier Science B.V. All rights reserved. doi:10.1016/S1386-6532(03)00013-1

118

Table 2 Indication

Patient group

Drug

Dosea

Routea

Durationa

Comment/caution

Herpes simplex virus Primary HSV

Uncomplicated

Aciclovir (incl. child /2 years) Valaciclovir Famciclovir Aciclovir Aciclovir

200 mg 5 /per day

Oral

5 days

Treatment must be started early for optimum effect

500 mg BD 250 mg TDS 100 mg 5 /per day

Oral Oral Oral

5 days 5 days 5 days

5 /10 mg/kg 8 hourly 500 mg/m2 8 hourly 250 mg/m2 8 hourly 10 mg/kg 8 hourly 15 mg/kg 8 hourly 500 mg/m2 8 hourly

IV IV IV IV IV IV

5 days 3 weeks 5 days 5 days 14 days / 14 days /

HSV encephalitis Recurrent HSV

Child under 2 years Severe disease Adult Neonatal disease Child 3 months /12 years Immunocompromised Adult Child

Aciclovir Aciclovir Aciclovir

200 mg 5 /per day

Oral

5 days

Immunocompromised

Valaciclovir Famciclovir Aciclovir

500 mg BD 125 mg BD 400 mg 5 /per day

Oral Oral Oral

5 days 5 days 5 days

Valaciclovir Famciclovir Aciclovir Aciclovir 5 % cream Penciclovir 1% cream Aciclovir 3% eye ointment Ganciclovir 0.15% eye drops

500 mg BD 500 mg BD 5 mg/kg 8 hourly 4 hourly 2 hourly during day 5/per day

Oral Oral IV TOP TOP TO EYE

5/per day until healed then 3/per day

TO EYE

5 days 7 days 5 days 5 /10 days 4 days To 3 days after healed To 7 days after healed

Suspected viral resistance

Foscarnet

40 mg/kg 8 hourly (slow infusion)

IV

Prophylaxis: genital recurrences

Aciclovir

400 mg BD (reduce dose with time) 500 mg OD 250 mg BD

Oral Oral Oral

200 /400 mg QDS

Oral

or 5 mg/kg 8 hourly 500 mg BD 100 /200 mg QDS

IV Oral Oral

800 mg 5 /per day 200 mg QDS

Oral Oral

Topical agents */skin -eye

Valaciclovir Famciclovir Prophylaxis: immunosuppression

Adult

Child under 2 years Varicella Zoster virus VZV (chickenpox)

Adult Child / B/2 years

Aciclovir (incl. child /2 years) Valaciclovir Aciclovir

Aciclovir

2 /3 weeks

Consider up to 15 mg/kg

Treatment must be started early for optimum effect

Longer courses may be required depending on symptom resolution

Do not use antiviral creams on mucosal surfaces. Herpetic keratitis may require systemic treatment

Avoid in mod-sev renal failure. Reduce dose if mild. Ensure good hydration monitor U&E and creatinine Suspend treatment for 2 recurrences after 6 /12 months

7 days 5 days

Erratum

Uncomplicated

Consider up to 15 mg/kg

Table 2 (Continued ) Indication

Patient group 2 /5 years 6 /12 years Severe disease Adult Child (3 months /12 years) Immunocompromised

Drug

Oral Oral

5 days 5 days

10 mg/kg 8 hourly 250 mg m2 8 hourly

IV IV

5 days 5 days

Longer courses may be required

Aciclovir

Longer courses may be required depending on symptoms 10 mg/kg 8 hourly 15 /18 mg/kg 8 hourly 500 mg/m2 8 hourly

IV IV IV

7 days 7 days 7 days

Aciclovir Valaciclovir Famciclovir

800 mg 5 /per day 1 g TDS 250 mg TDS or 750 mg OD

Oral Oral Oral

7 days 7 days 7 days

Immunocompromised

Aciclovir Valaciclovir Famciclovir

5 mg/kg 8 hourly 1 g TDS 500 mg TDS

IV Oral Oral

7 days 7 days 10 days

Longer courses may be required

Foscarnet

40 mg/kg 8 hourly (slow infusion)

IV

2 /3 weeks

See above re foscarnet

Ganciclovir Ganciclovir Valganciclovir Foscarnet Cidofovir

5 mg/kg 12 hourly 5 mg/kg 12 hourly 900 mg BD with food 60 mg 8 hourly 5 mg/kg 1 /per week (/ probenecid)

IV IV Oral IV IV

2 /3 weeks 2 /3 weeks 21 days 2 /3 weeks 2 weeks

Reduce dose if renal impairment. Monitor U&E Reduce dose if renal impairment. Monitor U&E

Fomivirsen

165 mg l /per week 330 mg 1 /per 2 weeks after relapse 5 mg/kg OD

Intravitreal Intravitreal

3 weeks For 2 doses

900 mg OD with food 1 g TDS with food 60 mg/kg OD up to 90 /120 mg/kg 5 mk/kg 1 /per 2 weeks 165 mg l /per 2 weeks 330 mg 1 /per 4 weeks after relapse

Oral Oral IV

Ganciclovir Aciclovir

l g TDS with food 10 mg/kg until engraftment then 800 mg QDS

Oral IV Oral

Zanamivir Amantadine

10 mg BD 100 mg OD

Inhaled Oral

Acute disease

Maintenance (those at risk of Ganciclovir relapse) Valganciclovir Ganciclovir Foscarnet Cidofovir Fomivirsen

Influenza Treatment

400 mg QDS 800 mg QDS

Comment/caution

Uncomplicated

Alternatives

Prophylaxis

Durationa

Solid organ transplant Bone marrow transplant

IV

Erratum

Suspected viral resistance Cytomegalovirus CMV disease CMV retinitis

Routea

Aciclovir

Adult */severe or late presentation Child Zoster (shingles)

Dosea

See above re foscarnet As for foscarnet PLUS: Prehydrate with IV fluids give 2 g oral probenecid 3 h before infusion and 1 g 2 and 8 h after Monitor visual fields and IOP

See notes above

IV Intravitreal Intravitreal

2

119

5 days 5 days

120

Table 2 (Continued ) Indication

Drug

Dosea

Routea

Durationa

Comment/caution

Zanamivir Amantadine

10 mg OD 100 mg OD

Inhaled Oral

6 weeks

3 Oseltamivir has recently been licensed

Ribavirin

3 /7 days

Teratogen (see text)

Palavizumab

20 mg/ml solution over 12 /18 Inhaled (see h per day or 60 mg/ml for 2 h text) BD IM 15 mg/kg 1 /per month

All patients Patients with good response factors

Lamivudine Interferon

100 mg OD 10 million units 3 /per week

Oral SC

12 months/ 4 months

4 4

First choice

Ribavirin (with interferon as bellow)

1 g OD (patient under 75 kg)

SC

6 /12 months

5

Patients where ribavirin is contraindicated

Interferon

1.2 g OD (patient over 75 kg) 3 million units 3/per week

SC SC

6 /12 months 12 months

Patient group

Prophylaxis RSV Treatment

Prophylaxis Hepatitis B virus Chronic disease

All doses from aBNF(43), 2002 and bPrentice et al., 1997; cCouch, 2000; dMalik and Lee, 2000; eBooth et al., 2001.

5 Pegylated interferon is likely to replace interferon

Erratum

Hepatitis C virus Chronic disease

RSV season